Chronic Wireless Communication Between Dual-Chamber Leadless Pacemaker Devices.

Aveir Leadless pacemaker dual-chamber i2i implant-to-implant communication

Journal

Heart rhythm
ISSN: 1556-3871
Titre abrégé: Heart Rhythm
Pays: United States
ID NLM: 101200317

Informations de publication

Date de publication:
18 Oct 2024
Historique:
received: 12 09 2024
revised: 27 09 2024
accepted: 12 10 2024
medline: 21 10 2024
pubmed: 21 10 2024
entrez: 20 10 2024
Statut: aheadofprint

Résumé

Aveir™ DR (Abbott) is a dual-chamber leadless pacemaker (LP) system with distinct atrial and ventricular LPs (ALP, VLP) that communicate wirelessly to deliver atrioventricular synchronous pacing. Success rates of these implant-to-implant (i2i™) transmissions have not been systematically evaluated. To evaluate chronic i2i success rates in a clinical setting. Patients meeting standard dual-chamber pacing indications were enrolled and implanted with dual-chamber LP systems as part of a prospective, international clinical trial ("Aveir DR i2i Study"). The percent of successful i2i transmissions from ALP-to-VLP (A-to-V) and VLP-to-ALP (V-to-A) were interrogated from LPs in de novo patients using the device programmer at implant, discharge, and at 1-, 3-, and 6-months post-implant (1M, 3M, 6M). 399 patients completed device implant and i2i diagnostic interrogation (62% male; age 69 years; 65% sinus node dysfunction, 32% AV block). Median A-to-V and V-to-A i2i success rates exceeded 90% of beats at all time-points from implant to 6M. The minority of patients with A-to-V or V-to-A i2i success in <70% of beats at implant (A-to-V: 19% of patients, V-to-A: 31% of patients) showed roughly 40% improvement by 1M, with this minority dropping to roughly 5% of patients by 6M. Improvement in i2i communication success may be attributed to reprogramming of i2i setting levels, natural changes in dominant posture, and device stabilization. Wireless implant-to-implant communication in the new dual-chamber leadless pacemaker system demonstrated successful transmissions in >90% of beats throughout the 6-month evaluation period. Communication success improved significantly over time post-implant for specific subgroups.

Sections du résumé

BACKGROUND BACKGROUND
Aveir™ DR (Abbott) is a dual-chamber leadless pacemaker (LP) system with distinct atrial and ventricular LPs (ALP, VLP) that communicate wirelessly to deliver atrioventricular synchronous pacing. Success rates of these implant-to-implant (i2i™) transmissions have not been systematically evaluated.
OBJECTIVE OBJECTIVE
To evaluate chronic i2i success rates in a clinical setting.
METHODS METHODS
Patients meeting standard dual-chamber pacing indications were enrolled and implanted with dual-chamber LP systems as part of a prospective, international clinical trial ("Aveir DR i2i Study"). The percent of successful i2i transmissions from ALP-to-VLP (A-to-V) and VLP-to-ALP (V-to-A) were interrogated from LPs in de novo patients using the device programmer at implant, discharge, and at 1-, 3-, and 6-months post-implant (1M, 3M, 6M).
RESULTS RESULTS
399 patients completed device implant and i2i diagnostic interrogation (62% male; age 69 years; 65% sinus node dysfunction, 32% AV block). Median A-to-V and V-to-A i2i success rates exceeded 90% of beats at all time-points from implant to 6M. The minority of patients with A-to-V or V-to-A i2i success in <70% of beats at implant (A-to-V: 19% of patients, V-to-A: 31% of patients) showed roughly 40% improvement by 1M, with this minority dropping to roughly 5% of patients by 6M. Improvement in i2i communication success may be attributed to reprogramming of i2i setting levels, natural changes in dominant posture, and device stabilization.
CONCLUSION CONCLUSIONS
Wireless implant-to-implant communication in the new dual-chamber leadless pacemaker system demonstrated successful transmissions in >90% of beats throughout the 6-month evaluation period. Communication success improved significantly over time post-implant for specific subgroups.

Identifiants

pubmed: 39427688
pii: S1547-5271(24)03446-5
doi: 10.1016/j.hrthm.2024.10.020
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Rahul N Doshi (RN)

HonorHealth Cardiac Arrhythmia Group, Scottsdale, Arizona, USA. Electronic address: rdoshi@honorhealth.com.

James E Ip (JE)

Weill Cornell Medicine/ New York Presbyterian Hospital, New York, New York, USA.

Pascal Defaye (P)

CHRU Albert Michallon, Grenoble, France.

Derek V Exner (DV)

Foothills Medical Centre, Calgary, Canada.

Vivek Y Reddy (VY)

Mount Sinai Fuster Heart Hospital, New York, NY, USA.

Gerhard Hindricks (G)

Heart Center Leipzig GmbH, Leipzig, Germany.

Robert Canby (R)

Texas Cardiac Arrhythmia Institute, Austin, Texas, USA.

Morio Shoda (M)

Tokyo Women's Medical University, Tokyo, Japan.

Maria G Bongiorni (MG)

San Rossore Private Hospital and Medical Center, Pisa, Italy.

Petr Neužil (P)

Na Homolce Hospital, Prague, Czech Republic.

Thomas Callahan (T)

Cleveland Clinic Foundation, Cleveland, Ohio, USA.

Nima Badie (N)

Abbott, Sunnyvale, California, USA.

David Ligon (D)

Abbott, Sunnyvale, California, USA.

Reinoud E Knops (RE)

Amsterdam UMC, Amsterdam, The Netherlands.

Classifications MeSH